New AI test could end ‘postcode lottery' for ‘game changer' prostate cancer drug
A study has found the technology can show medics the exact patients who will benefit most from a 'game changer' drug.
Abiraterone is a type of hormone therapy that works by blocking the production of testosterone, the hormone that fuels the growth of prostate cancer.
It is approved for use on the NHS in England for patients with advanced prostate cancer which has come back and spread to other parts of the body.
However, it is not approved for men who are newly diagnosed with high-risk prostate cancer that has not yet spread, despite it being available for these patients in Scotland and Wales for the past two years.
The new test, developed by Artera, uses AI to pick up features invisible to the human eye on images of tumour samples.
The study, led by The Institute of Cancer Research, London, and University College London (UCL), ran the test on biopsy images from more than 1,000 men who took part in the Stampede trial.
Patients were given a score of either biomarker-positive or biomarker-negative.
Researchers found abiraterone reduced the risk of death among biomarker-positive patients from 17% to 9%.
In biomarker-negative patients, the drug cut death risk from 7% to 4%, with researchers suggesting this indicates these men would benefit from standard therapy.
Nick James, a professor of prostate and bladder cancer research at The Institute of Cancer Research, London, and consultant clinical oncologist at The Royal Marsden NHS Foundation Trust, is chief investigator of Stampede and co-led the new study.
He said: 'This research shows that we can pick out the people who will respond best to abiraterone, and those who will do well from standard treatment alone – hormone therapy and radiotherapy.
'Access to this life-extending drug is currently a postcode lottery – with those living in Scotland and Wales able to receive the treatment for free.
'The NHS in England has previously decided that it would be too expensive to offer the drug. Since the patent expired in 2022, abiraterone costs just £77 per pack – compared with the thousands of pounds that new drugs cost.
'Previous research by my team has shown that preventing cancer relapses for these men would save more money than the drug costs to purchase.
'I truly hope that this new research – showing precisely who needs the drug to live well for longer – will lead to NHS England reviewing their decision not to fund abiraterone for high-risk prostate cancer that has not spread.'
Prof James also highlighted that while abiraterone can have 'spectacular' results, it does have side effects.
'Abiraterone has already hugely improved the outlook for hundreds of thousands of men with advanced prostate cancer,' he said.
'We know that for many men with cancer that has not yet spread, it can also have spectacular results.
'But it does come with side effects and requires additional monitoring for potential issues with high blood pressure or liver abnormalities.
'It can also slightly increase the risk of diabetes and heart attacks, so knowing who is most likely to benefit is very valuable.'
Experts hope the findings, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, may lead to a change in the availability of abiraterone in England.
Prof Kristian Helin, chief executive of The Institute of Cancer Research, said the drug has been a 'game changer for treatment of prostate cancer'.
'Alongside our mission to find smarter, kinder treatments, we must ensure we are matching the right drugs to the right patients,' he added.
'This research, using artificial intelligence, provides an innovative route to testing prostate cancer patients to determine their treatment.
'I hope that this can be implemented so that all men with prostate cancer who will benefit from abiraterone can do so.'
Dr Matthew Hobbs, director of research at Prostate Cancer UK, said: 'Prostate Cancer UK has been calling on the UK Government to approve this life-saving, cost-effective drug for over two years.
'These exciting results suggest a way to make this an even more cost-effective approach.
'We therefore echo the researchers' urgent call for abiraterone to be made available to those men whose lives it can save – men who, thanks to this research, we can now identify more precisely than ever before.'
A Department of Health and Social Care spokesperson said: 'We understand the frustration and upset of patients who cannot access this treatment.
'Abiraterone is available for some NHS patients in England with metastatic prostate cancer, and a decision to extend its use will be kept under review.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
43 minutes ago
- Daily Record
Vape ban fire fears as experts warn of 'ticking time bomb'
The ban on selling disposable vapes in the UK comes into force tomorrow, Sunday, June 1. A nationwide crackdown on disposable vapes comes into force tomorrow. From Sunday, June 1, it will be illegal to sell the single-use devices anywhere in the UK. The move is aimed at protecting the health of the nation, especially youngsters as the bright-coloured puffers with their sweet flavours have proved a hit with teens in recent years. NHS stats from 2024 showed that nearly a quarter of children in the age bracket of 11 to 15 had tried vaping, and almost one in 10 vaped frequently. The new law aims to deter young people and children from turning to the nicotine products, which have been found to have serious health consequences. The move is also aimed at protecting the environment, as almost five million vapes were littered or discarded every week last year, according to figures from Material Focus. Many vapes end up in landfill or the incinerator, where valuable materials are wasted instead of being recycled. Littered vapes can leak harmful chemicals into soil, rivers, and streams, and contain lithium which can cause fires. And the chance of fire has sparked a warning from experts who branded the devices "ticking time bombs" if they are not correctly recycled. Vapes contain lithium-ion batteries, and these can overheat and ignite when damaged or crushed. If vapes enter bin lorries or waste management facilities, they're at risk of catching fire. Data shows that vape-related fires are on the rise in the UK, with a massive surge of 348 per cent between 2020 and 2025. And this can be caused by people simply chucking vapes in their bins at home. Research from consumer safety charity Electrical Safety First found that this is the method that almost three in five vapers (58%) will use to dispose of their single-use puffers. But it is something that could see you fined up to £600 and potentially void your home insurance. Even more worryingly, the survey discovered that 71 per cent of Brits know that vapes can cause fires if chucked away improperly but most still plan on doing that anyway. In Slough earlier this month, a bin lorry caught fire due to a disposable vape and the crew were forced to dump five tonnes of rubbish in the middle of the road to stop the blaze engulfing the entire vehicle. Similar incidents have been reported in East Yorkshire and Manchester this year too. Giuseppe Capanna, product safety engineer at Electrical Safety First, said: "With the ban on disposable vapes fast approaching, we're urging people not to bin the battery. "These devices contain lithium-ion batteries that can explode or catch fire if damaged, creating a ticking time bomb that puts workers and communities at serious risk. "The safest option is to recycle them properly. You can recycle them through retail take back schemes or at a local recycling centre that has dedicated facilities.' Although it may seem easier just to dump your disposables in the nearest bin, there are many different options for getting rid of them more safely According to the team at Recycle Your Electricals, it can be as simple as taking your e-cigs back to the store where you bought them since all retailers that sell them must accept your old vapes, making it as easy to recycle them as it is to buy them Many local authorities collect electrical devices for recycling, either with your regular collection or by special arrangement. Contact your council to find out if that is possible where you live. You can also take vapes to your local tip, since most recycling centres have sections for electricals and batteries. If you are able to remove the battery, you can recycle it separately. If not, you can put the whole device in with the electrical recycling. Smaller recycling banks also often have a spot for electricals. This could be at your local supermarket or shop, in a car park, or even at a designated roadside stop. If you know of one such bank close to you, check out if they have electrical recycling facilities. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'.
Daily Mail
5 hours ago
- Daily Mail
NHS trust suggested trans staff wearing chest binders should have 'extra breaks to cope with tucking' away their genitals
An NHS trust reportedly suggested that its transgender colleagues should be given extra breaks if they wore chest binders or needed a break from tucking their genitals away. In an draft guidance report allegedly seen by The Telegraph, University Hospitals Sussex NHS Trust said its trans staff may need extra breaks in order to have time where they are not 'binding and tucking'. If the move had been accepted it would reportedly have been a first for the health service who currently offer no advice for trans people who use the methods to appear less masculine or feminine. Both practices are said to cause infections, inflammation and have been known to cause other painful health problems such as testicular torsion. And although the trust said the proposals would not be pursued, critics said the draft plans raised concerns about potential NHS policies. An extract from the proposed 15-page guidance titled, 'Supporting transgender and non-binary staff', reportedly read: 'Please note that transgender staff who wear chest binders (an item of clothing that compresses the chest and creates a more masculine chest contour), or who tuck (a way of obscuring genitals in order to create a smoother, more feminine appearance) may require extra scheduled breaks in their shift in order to have breaks from binding and tucking. 'Binding in particular can constrict breathing. If possible, provide a private space they are able to access in order to do so. It is helpful to have a conversation with the individual to understand if there are ways of presenting they wish to engage in that may require them to have extra breaks.' The newspaper says that some of the trust's LGBTQ+ staff put the document together last year. A former employee at the trust said if made no sense to prioritise the needs of 'one group of staff over everyone else'. They added that other colleagues who suffer from heavy periods or may have to pray multiple times per day were not receiving such allowances. Helen Joyce, the director of advocacy at human rights charity Sex Matters, told the newspaper that the proposals 'should never have made it onto paper, even as a draft'. She said: 'Tucking genitals and binding breasts are culturally motivated actions that cause permanent physical damage, just like breast ironing and the use of neck coils. The only difference is that self-harm in the name of trans identity is high status and fashionable.' Ms Joyce added that the plans would have been 'disgraceful coming from a healthcare body' and that she was glad they had not been approved. A spokesman for the trust said that the proposals had been submitted by a colleague to a manager in February but that it 'was not accepted'. They told the newspaper that the draft 'is not trust policy or guidance' and that 'it never has been and never will be'.
Daily Mail
5 hours ago
- Daily Mail
Major breakthrough in cancer caused by oral sex - as cases continue to climb in under 50s
Thousands of patients with cancers of the head and neck have been thrown a lifeline by 'world changing' drug that dramatically slows the spread of the disease. The injection, called pembrolizumab, helps the immune system spot hidden cancer cells in the body. It is currently offered to NHS patients with advanced lung, breast and cervical cancers—but expert believe it hold far wider promise. Also known by the brand name Keytruda, a groundbreaking trial found the drug kept head and neck cancers at bay for five years compared to 30 months with standard treatments, including surgery, chemotherapy and radiotherapy. It also slashed the risk of the disease returning elsewhere in the body. Researchers presenting the findings at the American Society of Clinical Oncology conference in Chicago said the injection 'could change the world for these patients' offering them 'years longer than the current standard treatments'. Head and neck cancer is an umbrella term for cancers of the mouth, throat, voice box, nose, sinuses and salivary glands. Until recently, experts believed the main causes were lifestyle-related—particularly smoking and heavy drinking. In recent years, research has suggested that human papillomavirus (HPV) may be responsible for up to 70 per cent of head and neck cancers. HPV is a common virus spread through close contact, including sex, and is usually harmless. However, in some cases—for reasons not fully understood—it can trigger cancerous changes in healthy tissue. The virus is already known to cause cervical, anal and penile cancers. A rise in head and neck cancers, particularly among younger and middle-aged patients, has been linked to oral sex. In the global trial, carried out across 24 countries involving more than 700 head and neck cancer patients, 363 received pembrolizumab followed by standard treatment. The remainder had standard treatment only. Pembrolizumab is a checkpoint inhibitor—it works by helping the immune system recognise and fight cancer. Scientists found the cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care. After three years, the risk of cancer returning somewhere else in the body was also 10 per cent lower among those on pembrolizumab. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades. 'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas. 'This research shows that immunotherapy could change the world for these patients—it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.' Professor Harrington added that the drug 'dramatically increases the duration of disease remission—for years longer than the current standard treatments'. 'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said. Laura Marston, 45, from Derbyshire was diagnosed with stage four tongue cancer in 2019 after an ulcer on her tongue didn't heal. She was later referred to The Royal Marsden where she joined the trial. 'I was so excited to be on a clinical trial and knowing I was in the best hands was really reassuring,' she said. 'As part of the trial I underwent two rounds of immunotherapy before undergoing surgery. 'In the months following my surgery I had to relearn how to eat and talk again while also having ten more infusions of immunotherapy, chemotherapy, and radiotherapy. 'My clinical team were amazing and went above and beyond for anything I needed. I am amazed I am still here six years later, this treatment has given me the gift of life.' Cancers that affect the head and neck are the eighth most common form of cancer overall in the UK, although they are two to three times more common in men than in women. About 12,500 new cases are diagnosed each year, according to Cancer Research UK, and incidences are on the rise. Dr Lyndsy Ambler, Cancer Research UK senior strategic evidence manager, said: 'Around 4,100 people die from head and neck cancers every year—that's approximately 11 deaths every day. 'Any potential new treatment options for a disease where there has been limited progress for decades are very welcome. 'Pembrolizumab's potential benefit for people with head and neck cancer could represent a significant step forward in how we treat the disease.'
